Clinical Trial Update: Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the MEK inhibitor GSK1120212 in patients with uveal melanoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• GSK1120212 (trametinib)

Snippet

Sponsor: GlaxoSmithKline | Conditions: GNA11 Mutation-positive Metastatic Melanoma, GNAQ Mutation-positive Metastatic Melanoma | Phase 2 | Status: WITHDRAWN